Urszula A. Sobol
Experienced in Chronic B-Cell Leukemia (CBCL)

Dr. Urszula A. Sobol

Hematology | Oncology
Aurora Healthcare
Illinois Cancer Specialists
880 W Central Rd, 
Arlington Heights, IL 
On Staff At
Experienced in Chronic B-Cell Leukemia (CBCL)
Aurora Healthcare
Illinois Cancer Specialists
880 W Central Rd, 
Arlington Heights, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Urszula Sobol is a Hematologist and an Oncologist in Arlington Heights, Illinois. Dr. Sobol is rated as an Experienced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Familial Pancreatic Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Colorectal Cancer.

Her clinical research consists of co-authoring 4 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Loyola Chicago Stritch School of Medicine, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine, Medical Oncology
Fellowships
Loyola Chicago Stritch School of Medicine, Hematology/Oncology
Hospital Affiliations
Advocate Lutheran General Hospital
Alexian Brothers Medical Center 1
Northwest Community Hospital 1
Languages Spoken
English
Polish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Illinois Cancer Specialists
880 W Central Rd, Arlington Heights, IL 60005
Call: 847-259-4482

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 17, 2025
Intervention Type: Drug
Study Drugs: Alpelisib, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
Study Phase: Phase 3
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Biological, Drug
Study Drugs: Oregovomab, Paclitaxel, Carboplatin
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 3
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Enrollment Status: Terminated
Publish Date: July 27, 2022
Intervention Type: Drug, Other
Study Drug: Varenicline
Study Phase: Phase 3
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Enrollment Status: Terminated
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 2
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

4 Total Publications

A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies.
A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies.
Journal: Bone marrow transplantation
Published: February 23, 2015
View All 4 Publications
Similar Doctors
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Shuo Ma
Hematology | Oncology
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Shuo Ma
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (22.9 miles away)
866-587-4322
Experience:
32+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shuo Ma is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Ma has been practicing medicine for over 32 years and is rated as an Elite provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration.

Elite in Chronic B-Cell Leukemia (CBCL)
Dr. David Grinblatt
Hematology
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. David Grinblatt
Hematology

Endeavor Health Medical Group

1300 Oak Ave, 
Evanston, IL 
 (15.9 miles away)
847-869-1300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Grinblatt is a Hematologist in Evanston, Illinois. Dr. Grinblatt is rated as a Distinguished provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Martin S. Tallman
Hematology
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Martin S. Tallman
Hematology
675 N Saint Clair St, Galter 21-100, 
Chicago, IL 
 (22.6 miles away)
312-695-0990
Languages Spoken:
English
See accepted insurances

Martin Tallman is a Hematologist in Chicago, Illinois. Dr. Tallman is rated as an Elite provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Acute Promyelocytic Leukemia, Acute Myeloid Leukemia (AML), Hairy Cell Leukemia (HCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

VIEW MORE CHRONIC B-CELL LEUKEMIA (CBCL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sobol's expertise for a condition
ConditionClose
    • Distinguished
    • Agranulocytosis
      Dr. Sobol is
      Distinguished
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Anal Cancer
      Dr. Sobol is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Breast Cancer
      Dr. Sobol is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Chronic Familial Neutropenia
      Dr. Sobol is
      Distinguished
      . Learn about Chronic Familial Neutropenia.
      See more Chronic Familial Neutropenia experts
    • Colorectal Cancer
      Dr. Sobol is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Endometrial Cancer
      Dr. Sobol is
      Distinguished
      . Learn about Endometrial Cancer.
      See more Endometrial Cancer experts
    View All 13 Distinguished Conditions
    • Advanced
    • Adult Immune Thrombocytopenia
      Dr. Sobol is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Sobol is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Sobol is
      Advanced
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    • Deep Vein Thrombosis
      Dr. Sobol is
      Advanced
      . Learn about Deep Vein Thrombosis.
      See more Deep Vein Thrombosis experts
    • Diffuse Large B-Cell Lymphoma (DLBCL)
      Dr. Sobol is
      Advanced
      . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
      See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
    • EGFR Positive Lung Cancer
      Dr. Sobol is
      Advanced
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    View All 30 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Sobol is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Sobol is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Sobol is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Sobol is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Acute Myelomonocytic Leukemia
      Dr. Sobol is
      Experienced
      . Learn about Acute Myelomonocytic Leukemia.
      See more Acute Myelomonocytic Leukemia experts
    • Acute Promyelocytic Leukemia
      Dr. Sobol is
      Experienced
      . Learn about Acute Promyelocytic Leukemia.
      See more Acute Promyelocytic Leukemia experts
    View All 123 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.